MX366983B - Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. - Google Patents

Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.

Info

Publication number
MX366983B
MX366983B MX2014008780A MX2014008780A MX366983B MX 366983 B MX366983 B MX 366983B MX 2014008780 A MX2014008780 A MX 2014008780A MX 2014008780 A MX2014008780 A MX 2014008780A MX 366983 B MX366983 B MX 366983B
Authority
MX
Mexico
Prior art keywords
same
inhibitors containing
naphthyridine derivatives
melk inhibitors
melk
Prior art date
Application number
MX2014008780A
Other languages
English (en)
Other versions
MX2014008780A (es
Inventor
Yusuke Nakamura
Joel R Walker
Yo Matsuo
Shoji Hisada
Feryan Ahmed
Raymond Huntley
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2014008780A publication Critical patent/MX2014008780A/es
Publication of MX366983B publication Critical patent/MX366983B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención está dirigida a un compuesto representado por la fórmula (I), que comprende un derivado de 1,5-naftiridina; en una modalidad, el derivado de 1,5-naftiridina de fórmula (I) tiene actividad inhibitoria contra la cinasa de cierre de leucina embrionaria materna (MELK); la presente invención también incluye un método para preparar el derivado de 1,5-naftiridina de fórmula (I); la presente invención también incluye una composición farmacéutica que contiene el derivado de 1,5-naftiridina de fórmula (I) como ingrediente activo.
MX2014008780A 2012-01-19 2012-12-21 Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. MX366983B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588496P 2012-01-19 2012-01-19
PCT/US2012/071434 WO2013109388A2 (en) 2012-01-19 2012-12-21 1,5-naphthyridine derivatives and melk inhibitors containing the same

Publications (2)

Publication Number Publication Date
MX2014008780A MX2014008780A (es) 2014-10-23
MX366983B true MX366983B (es) 2019-08-01

Family

ID=48799799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008780A MX366983B (es) 2012-01-19 2012-12-21 Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.

Country Status (16)

Country Link
US (2) US9067937B2 (es)
EP (1) EP2753329B1 (es)
JP (1) JP6159948B2 (es)
KR (1) KR101920109B1 (es)
CN (1) CN104968345B (es)
AU (1) AU2012366148B2 (es)
BR (1) BR112014014877B1 (es)
CA (1) CA2857346C (es)
DK (1) DK2753329T3 (es)
ES (1) ES2642720T3 (es)
IL (1) IL233529A (es)
MX (1) MX366983B (es)
RU (1) RU2645339C1 (es)
SG (1) SG11201403335WA (es)
TW (2) TWI623536B (es)
WO (1) WO2013109388A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012016082A1 (en) * 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US10254283B2 (en) 2013-11-12 2019-04-09 Dana-Farber Cancer Institute, Inc. Biomarker for MELK activity and methods of using same
CN106232878A (zh) * 2013-11-12 2016-12-14 丹娜法伯癌症研究院 Melk活性的生物标记物及使用其的方法
CN107530353A (zh) 2015-03-04 2018-01-02 丹娜法伯癌症研究院 Melk的三环激酶抑制剂和使用方法
JP6873145B2 (ja) * 2016-01-14 2021-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
US11066477B2 (en) 2016-08-31 2021-07-20 Oncotherapy Science, Inc. Monoclonal antibody against MELK and utilization thereof
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
US10981896B2 (en) 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN111171020A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5240916A (en) 1989-07-27 1993-08-31 Dowelanco Naphthyridine derivatives
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
DE602005025231D1 (de) 2004-08-10 2011-01-20 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
EP2311983A1 (en) 2005-02-10 2011-04-20 Oncotherapy Science, Inc. Method of treating bladder cancer using siRNA
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
CN101466682A (zh) * 2006-04-14 2009-06-24 阿斯利康(瑞典)有限公司 作为csf-1r激酶抑制剂的4-苯胺基喹啉-3-甲酰胺
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
EP2332939A1 (en) * 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
WO2012016082A1 (en) * 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same

Also Published As

Publication number Publication date
DK2753329T3 (en) 2017-10-23
BR112014014877B1 (pt) 2020-09-08
WO2013109388A3 (en) 2015-02-05
IL233529A0 (en) 2014-08-31
RU2645339C1 (ru) 2018-02-21
TWI623536B (zh) 2018-05-11
BR112014014877A2 (pt) 2017-06-13
JP2015513313A (ja) 2015-05-07
EP2753329B1 (en) 2017-08-09
US20150005302A1 (en) 2015-01-01
CA2857346A1 (en) 2013-07-25
US20150328225A1 (en) 2015-11-19
EP2753329A2 (en) 2014-07-16
CA2857346C (en) 2019-06-04
WO2013109388A8 (en) 2013-09-26
AU2012366148A1 (en) 2014-06-05
IL233529A (en) 2017-10-31
TWI623537B (zh) 2018-05-11
EP2753329A4 (en) 2015-11-25
JP6159948B2 (ja) 2017-07-12
MX2014008780A (es) 2014-10-23
TW201734015A (zh) 2017-10-01
TW201333005A (zh) 2013-08-16
AU2012366148B2 (en) 2016-12-01
US9067937B2 (en) 2015-06-30
KR101920109B1 (ko) 2018-11-19
CN104968345A (zh) 2015-10-07
WO2013109388A2 (en) 2013-07-25
SG11201403335WA (en) 2014-09-26
CN104968345B (zh) 2018-05-08
ES2642720T3 (es) 2017-11-17
US9345709B2 (en) 2016-05-24
KR20140115356A (ko) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2013001201A (es) Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
PH12018501096A1 (en) Modulators of chemokine receptors
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
MA39749A (fr) Dérivés de pipéridine-dione
IN2015DN00598A (es)
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
MX2015002040A (es) Baricitinib deuterado.
CR20130539A (es) Triazolopiridinas
UY34654A (es) Inhibidores de la beta-secretasa
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
MX2017016030A (es) Derivado de dihidropirrolopirazol sustituido.
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
SG10201805896SA (en) PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
IN2014DN07996A (es)
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
WO2016190501A8 (ko) 유기 광전자 소자용 화합물, 유기 광전자 소자용 조성물, 및 이를 포함하는 유기 광전자 소자 및 표시장치
NZ627473A (en) Aryloxyacetamide compound and pesticide
MX2015008829A (es) Momelotinib deuterado.
PH12015501146A1 (en) Hydantoin derivative
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX2015012610A (es) Pacritinib deuterizado.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration